Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06672692

A Multi-Site Clinical Evaluation of the LIAISON NES FLU A/B, RSV & COVID-19 Assay in Symptomatic Patients

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
1,000 (estimated)
Sponsor
DiaSorin Molecular LLC · Industry
Sex
All
Age
Healthy volunteers
Not accepted

Summary

The DiaSorin Molecular LIAISON® NES FLU A/B, RSV \& COVID-19 real-time polymerase chain reaction (RT-PCR) assay is intended for use on the DiaSorin LIAISON® NES instrument for the in-vitro qualitative detection and differentiation of nucleic acid from influenza A, influenza B, RSV and SARS-CoV-2 virus from dry nasal swabs (NS) from human patients with signs and symptoms during the acute phase of respiratory tract infection in conjunction with clinical and epidemiological risk factors. The LIAISON® NES FLU A/B, RSV \& COVID-19 assay is intended for use as an aid in the differential diagnosis of influenza A, influenza B, RSV and SARS-CoV-2 infection in a professional laboratory setting. Negative results do not preclude influenza A, influenza B, RSV or SARS-CoV-2, infection and should not be used as the sole basis for patient management decisions. The assay is not intended to detect the presence of the influenza C virus.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTLIAISON NES FLU A/B, RSV & COVID-19The LIAISON® NES FLU A/B, RSV \& COVID-19 assay used on the LIAISON® NES instrument is a real-time PCR system that enables the direct amplification, detection and differentiation of Flu A viral RNA, Flu B viral RNA RSV viral RNA, and SARS-CoV-2 RNA from dry nasal swabs. Nasal Swabs can be professionally collected by a Healthcare Provider or self-collected by the patient under the supervision of the healthcare provider. The collected nasal swab can then be directly loaded into the cartridge without nucleic acid extraction.

Timeline

Start date
2024-09-30
Primary completion
2025-03-01
Completion
2025-05-01
First posted
2024-11-04
Last updated
2024-11-04

Locations

3 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT06672692. Inclusion in this directory is not an endorsement.